Polaryx Therapeutics Inc (PLYX)

• Market cap: $160M
• 1 day: -7.38%
• 5 days: -34.56%
• 1 month: -45.06%
• 3 months: -6.35%
• 6 months: -90.31%
• Year to date: -90.31%
• 1 year: -90.31%
• 5 years: -90.31%
• 10 years: -90.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.